The same metabolite, imidazole propionate (ImP), was already found to be associated with diabetes and heart failure. See for example this study in Nature Communications (2020): https://www.nature.com/articles/s41467-020-19589-w.

I think the value of the current study in Nature is that "ImP administration to atherosclerosis-prone mice fed with chow diet was sufficient to induce atherosclerosis without altering the lipid profile, and was linked to activation of both systemic and local innate and adaptive immunity and inflammation.", i.e. they provided evidence of causality in a mechanistic way, with an intervention.

However, the newspaper article overplayed novelty. ImP and other metabolites from gut bacteria have already been linked to atherosclerosis.

▲

elcritch 10 hours ago | parent [-]

Anyone know if there’s lab tests for ImP already? Is it a common or well known enough target?

	▲	drjasonharrison 6 hours ago \| parent \| next [-]
		Another paper describes how imidazole propionate serum levels were measured: https://www.nature.com/articles/s41467-020-19589-w """Imidazole propionate serum measurements ImP was quantified using ultra-performance liquid chromatography coupled to tandem mass spectrometry according to previous work. Briefly, serum samples were extracted with 3 volumes of ice-cold acetonitrile containing internal standards (13C3-labeled ImP and urocanate). After derivatization to butyl esters using 5% hydrochloric acid in butanol, the samples were separated on a C18 column using a gradient consisting of water and acetonitrile. Quantification was made using an external calibration curve16.""" So yes, but no.
	▲	nextos 9 hours ago \| parent \| prev [-]
		These are typically measured using liquid chromatography coupled to tandem mass spectrometry. That also gives the opportunity to measure thousands of other metabolites, and thus get a broader picture of health. Unfortunately, commercial B2C metabolomics is not there yet. It's mostly used in population genomics research.